Ignite Creation Date:
2024-05-06 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06198907
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-10
First Post:
2023-12-28
Brief Title:
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung CancerNSCLC
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization Data
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Class:
OTHER
Study ID:
DZ2023J0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Lead Sponsor Class:
OTHER
Responsible Party:
Jie Wang
Responsible Party Title:
Chief Physician
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Dizal Pharmaceuticals | INDUSTRY |